Skip to main content

Table 2 Analgesic outcomes

From: Intrauterine lidocaine and naproxen for analgesia during intrauterine device insertion: randomized controlled trial

Characteristic

Lidocaine/Naproxen

Lidocaine/Placebo

Saline/Naproxen

Saline/Placebo

P

Physician pain assessment

0.77 ± 0.11

0.56 ± 0.09

0.48 ± 0.11

0.59 ± 0.8

0.238

Visual analog pain score

3.38 ± 2.49

2.87 ± 2.13

3.09 ± 2.18

3.62 ± 2.45

0.456

Post procedure analgesia

    

0.568

 Yes

10 (25)

8 (20)

9 (22.5)

12 (30.8)

 

 No

28 (70)

28 (70)

31 (77.5)

22 (56.4)

 

Satisfaction with procedure

4.36 ± 0.84

4.26 ± 0.94

4.3 ± 0.94

4.4 ± 0.9

0.910

Satisfaction with IUD (Day 30)

    

0.701

 Levonorgestrel 52 mg

4.40 ± 0.75

4.36 ± 0.97

4.35 ± 1.1

4.38 ± 0.89

 

 Copper T380A

4.31 ± 0.95

4.16 ± 0.92

4.3 ± 0.81

4.47 ± 0.94

 

Physician pain assessment

    

0.31

 Levonorgestrel 52 mg

0.90 ± 0.72

0.50 ± 0.11

0.55 ± 0.18

0.53 ± 0.12

 

 Copper T380A

0.63 ± 0.13

0.63 ± 0.14

0.40 ± 0.11

0.63 ± 0.11

 

Visual analog pain score

 Levonorgestrel 52 mg

3.55 ± 0.55

2.45 ± 0.44

2.85 ± 0.45

3.26 ± 0.54

0.09

 Copper T380A

3.26 ± 0.59

3.32 ± 0.52

3.35 ± 0.52

4.00 ± 0.58

 

Post procedure analgesia

 Levonorgestrel 52 mg

    

0.65

 Yes

3 (16) [0.33]

3 (17) [0.23]

5 (25) [0.09]

5 (31) [0.64]

 

 No

16 (84) [0.09]

15 (83) [0.06]

15 (75) [0.02]

11 (69) [0.18]

 

 Copper T380A

    

0.43

 Yes

7 (41) [0.45]

5 (28) [0.10]

4 (20) [0.89]

7 (41) [0.45]

 

 No

10 (59) [0.21]

13 (72) [0.05]

16 (80) [0.42]

10 (59) [0.21]

 
  1. Data are mean ± standard deviation, n%, [X2] unless otherwise specified